Zantac Lawsuit


Researching drug company and regulatory malfeasance for over 16 years
Humanist, humorist
Showing posts with label Japan. Show all posts
Showing posts with label Japan. Show all posts

Friday, June 23, 2017

Prozac: Three Blind Mice






Three blind mice, three blind mice,
See how they run, see how they run,
They all ran after the farmer's wife,
Who cut off their tails with a carving knife,
Did you ever see such a thing in your life,
As three blind mice?


Most believe the author of Three Blind Mice was a teenager named Thomas Ravenscroft. The origin of the words, according to many historians, stem from Queen Mary I and her staunch Catholic beliefs. due to her violent persecution of Protestants, she was known as 'Bloody Mary'. The reference to 'farmer's wife' in Three Blind Mice refers to the huge estates she possessed. The 'three blind mice' were three Protestants convicted of plotting against Queen Mary I.  She did not have them dismembered and blinded as inferred in Three Blind Mice, she had them burnt at the stake! 

Ah, don't you just love the morals and ethics of religion! Even today we still see people being killed in the name of something that cannot be seen or heard. History shows that religious books have been responsible for many deaths, or rather the way religious scriptures are been interpreted. The Three Blind Mice rhyme has similarities to a recent study in Japan.

The study, sponsored in part by Takeda Pharmaceutical Co. Ltd., involved mice pups bred to mimic the distinctive behaviors and brain abnormalities seen in autism. After inducing autistic traits, the mice were fed Prozac. The authors claim Prozac caused dramatic improvements in the animal's social interactions and communication patterns. The Prozac, which was administered through the mother’s milk for 19 days. Furthermore, according to the study, "newborn mice got a daily injection of Prozac in their first six days of life, the treatment appeared to restore normal vocalization patterns and reduce anxiety-like behaviors well into adulthood."

The study is littered with assumptions and seems to promote a chemical imbalance theory that both humans and mice allegedly have. The study doesn't seem to explain what was done to impair the animal's brain function. What it does claim is that Prozac improved the brain damage the researchers caused. 

It claims to show that Prozac cleared whatever was induced in the mice so, in essence, this could just possibly be one drug counteracting another drug.

The spin in this study is obvious. The authors have induced a series of brain abnormalities in mice pups then made claims that these abnormalities are almost identical to the abnormalities found in people with autism.

Here's the irony: Toxic exposures during pregnancy, such as the use of antidepressants, can disrupt brain processes before birth and shortly afterward. So, if antidepressants can disrupt the brain process before and after birth, why not treat that with, um, another antidepressant!

It must have been a slow news day at the Los Angeles Times whose health corespondent, Melissa Healy, ran with the study. Her article is littered with assumptions. She claims Prozac, "is thought to elevate mood and quell anxiety by increasing the availability of the neurotransmitter serotonin in the spaces between certain types of brain cells." I suspect her article is mainly a reprinted press release.

The key word here is "thought." Anything that follows it can, and should, be taken with a pinch of salt. It's clever marketing because our eyes are drawn to the science when, in actual fact, there is no science, it's just supposition.

Furthermore, the jounalist states, "Research on humans suggests that, during early brain development, those who will go on to develop autism have unusually low levels of serotonin in critical areas of the brain."

Now, here's a game for you all. What is the keyword in the above sentence?

Answers in the comments section or on my Facebook page please.

Science is an intellectual and practical activity encompassing the systematic study of the structure and behavior of the physical and natural world through observation and experiment. This Japanese study has done none of that.

Don't you just love the morals and ethics of clinical trials and unscientific journalsm reporting!

Full study here.

LA Times article here.

Bob Fiddaman









Tuesday, August 19, 2014

Antidepressant Aggression, the MHRA Perspective








Last month I wrote a piece entitled, 'Antidepressants: The Power To Harm' which, basically, highlighted the Japanese drug regulator and the Japanese Ministry of Health, Labour and Welfare. [MHLW]

A 2009 review of antidepressants in Japan [1] resulted in MHLW issuing an alert to patients and their families to pay due attention to changes in patient condition during the course of treatment. On May 8, 2009, MHLW required marketing authorization holders [MAHs] to revise precautions in package inserts.

They found that causality between SSRi antidepressants and harmful behavior to others could not be denied in 2 cases of reported adverse reactions associated with fluvoxamine maleate and 2 cases of reported adverse reactions associated with paroxetine hydrochloride hydrate. For the remaining 35 cases of adverse reactions, causality between the drug and adverse reactions was considered unknown.

After reading this review I wrote to the British drug regulator, the MHRA.

Dear Sir/Madam,
I would like to know if the MHRA have any information, be it by study or review, regarding SSRi adverse reactions of aggression including harmful behavior to others (including injury). 
Please state if any alerts to patients and their families have ever been sent out regarding this issue.
Please state if any revision to package inserts have been made regarding this issue.

The MHRA have now answered and, it has to be said, it would appear that patient welfare is far higher on the list in Japan than it is in the UK.

First off, their cover letter to me.




I like the final paragraph...

"The information supplied in response to your request is the copyright of MHRA and/or a third party or parties, and has been supplied for your personal use only. You may not sell, resell or otherwise use any information provided without prior agreement from the copyright holder."

I'm not going to bother asking the MHRA if I am allowed to republish, what I deem as, important safety information regarding SSRi use and aggression. They've used this threat before with me, see 'The evidence, however, is clear, the Seroxat scandal'. [2]


The MHRA have provided me with 30 pages of information with regard to the question I put to them, much of which is redacted [blacked out]

It would be pointless to post all 30 pages but those wishing to scrutinize can request a copy from me by emailing me.

Some points...

The information sent to me from the MHRA was taken from meetings that occurred between the years 1996 and 2001.

Contrast that to the Japanese information on SSRis and aggression. Their information is more up to date, in fact it is 8 years more up to date than what the MHRA have given me.

The MHRA, or the data they sent me, points to two SSRis causing aggression. Fluoxetine and Paroxetine, namely, Prozac and Seroxat (Paxil)

Remarkably these findings of aggression with Prozac and Seroxat use have been played down by claiming that the reporting rates of aggression increased when stories started appearing in the media. The MHRA do not balance this claim, for instance, (i) the reporting rates may have increased because patients may not have known that the MHRA actually collected such reports and (ii) consumers may have attributed their aggression and suicidal thinking to their illness, opposed to it being a possible adverse reaction to the drug they were taking.

Page 23 of the 30 page document they sent me is quite telling. [Fig 1]


Fig 1

So, when there is a clear sign that aggression is occurring during Prozac and/or Seroxat treatment it has, if you believe the above, nothing to do with the drug/s, it is possibly a "separate event from the underlying illness" or it's "part of a discontinuation syndrome", or maybe the aggression has appeared because of the removal of the therapeutic benefits of the drug.

Once again, the suggestion of media reports on antidepressants and the suicide link are mentioned. It's almost as if they [the committees who reviewed the aggression link in SSRi use] are putting something in place. Rather than look at the blindingly obvious problem they chose to deflect and lay the blame on intense media reporting.

Now, contrast this stance with those of the Japanese.

2009:

The Japanese Ministry of Health, Labour and Welfare issued an alert to patients and their families to pay due attention to changes in patient condition during the course of treatment. On May 8, 2009, MHLW required marketing authorization holders [MAHs] to revise precautions in package inserts.

The above was based on a review where they found an association with SSRis and aggression.

No pussy-footing around, no blaming the media, no blaming a discontinuation syndrome or no blaming the underlying illness causing the aggression. Moreover, the  Japanese Ministry of Health, Labour and Welfare sent an alert out to patients and their families about their findings.

I don't know about you but if one regulator flags a warning about patients becoming aggressive on antidepressants then other regulators around the world should act promptly.

Judging by the material sent to me by the MHRA, they put the SSRi aggression link to bed in 2002 and have done nothing more about it since then.

The MHRA is responsible for regulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe.

Oh really?



Bob Fiddaman


1. 2009 Selective Serotonin Reuptake Inhibitors and Aggression [Japanese Review] [Link]
2. The evidence, however, is clear, the Seroxat scandal. [Link]

Tuesday, July 29, 2014

Antidepressants: The Power To Harm





Much has been said about the suicide link with antidepressant use. I think we should accept that antidepressants can induce suicide given that the manufacturers and regulators have now admitted this one small fact that they previously [conveniently] omitted.

If a person can kill themselves due to an adverse reaction to a drug then could they also harm others?

In cases of homicide the antidepressant defence has been used many times, "My client was under the influence of an antidepressant and had homicidal thoughts your Honour".

Those that use such a defence are ridiculed because those that manufacture these types of drugs refuse to admit that their products can induce acts of homicide in those who take them.

Two high profile cases involve three SSRi type drugs, namely, Citalopram [known as Celexa in the US] and Seroxat [known as Paxil in the US] and Prozac.



Shane Clancy (22) drove to the quiet residential area of Cuala Grove in Bray where he unleashed an attack of psychotic proportions on his ex-girlfriend and her new boyfriend. Sebastian Creane. Creane's brother, Dylan, was stabbed nine times when he came to his aid.

The following afternoon, August 16, 2009, Shane Clancy's body was found in the back garden at Cuala Grove. He had stabbed himself 19 times.

The inquest into Shane's death returned an open verdict. The jury wasn't satisfied that he had intended to take his own life. Shane had toxic levels of citalopram, in his system. [More here]

David Crespi was alone with his twin daughters when he stabbed them to death, then called 911 to report the murder. The cocktail of drugs that his wife said pushed him over the edge was Prozac, Ambien, Trazadone and Lunesta. He'd been taking them for one to three weeks.

David Crespi entered guilty plea came to avoid the death penalty, but it led to a life sentence with no chance of parole. [More here]



There are those that refuse to accept that the antidepressants in the above cases played any part in the decisions of those who carried out these violent acts, opting instead to blame the 'mental illness'.

What if evidence could be provided, would it ease the pain of those left behind to pick up the pieces?

Exactly who are the victims here?

Those who were killed, the loved ones of those who were killed or those who carried out the homicide?

Well, all of them.

A 2009 review of antidepressants in Japan has been flying under the radar for some time and it was only by chance that I happened to find it via the Japanese Medicine Regulatory website.

The Japanese Ministry of Health, Labour and Welfare [MHLW]  reviewed reported adverse reactions of aggression, etc. including harmful behavior to others (including injury) associated with SSRIs or SNRIs.

MHLW issued an alert to patients and their families to pay due attention to changes in patient condition during the course of treatment. On May 8, 2009, MHLW required marketing authorization holders [MAHs] to revise precautions in package inserts.

Here's what they found...

"After a careful review of the 39 cases of harmful behavior to others including injury (including 4 potential episodes associated with milnacipran hydrochloride that could have resulted in harmful behavior) identified from the clinical course, causality between the drug and harmful behavior to others could not be denied in 2 cases of reported adverse reactions associated with fluvoxamine maleate and 2 cases of reported adverse reactions associated with paroxetine hydrochloride hydrate. For the remaining 35 cases of adverse reactions, causality between the drug and adverse reactions was considered unknown.  

"In light of the above findings and discussions amongst specialists, it is considered necessary to add the following precautionary statements to the “Important Precautions” section of package inserts: 1) Episodes of anxiety, irritation, excitement, panic attack, irritability, hostility, aggression, and impulsivity have been reported; 2) In patients with these symptoms or behavior, exacerbation of underlying disease, harmful behavior to others, etc. have been reported, though causality with the drugs is not clear; 3) Patients should be carefully monitored for changes in their clinical condition; 4) Patients’ families should be given full information on risks associated with changes in behavior such as excitement, aggression, irritability, etc., and an exacerbation of underlying disease, and be instructed to keep in close contact with the physician."

I wrote to the British drug regulator, the MHRA and asked them the following...

Dear Sir/Madam,
I would like to know if the MHRA have any information, be it by study or review, regarding SSRi adverse reactions of aggression including harmful behavior to others (including injury).
Please state if any alerts to patients and their families have ever been sent out regarding this issue.
Please state if any revision to package inserts have been made regarding this issue.

The MHRA have deemed that my query falls under the Freedom of Information Act and that I should receive a reply within 20 working days.

I'll keep you updated of any reply they send me.

Next time you read about a gun slaying in an American school it may be worth taking this Japanese review into account.

Next time you read of a murder carried out by someone who, just like the above three cases, were your normal, average, hard working male... then take the Japanese review into account.

Here's a recent one that raises all the red flags, for me at least.

The review by the  Japanese Ministry of Health, Labour and Welfare can be downloaded here.

Bob Fiddaman.





Wednesday, September 18, 2013

Why Was the Japanese Paxil Pediatric Study Terminated?




Regular readers of this blog will know how I broke the news back in 2009 regarding GlaxoSmithKline's attempts to push Paxil [known as Seroxat in UK] on kids in Japan.

I was so outraged at this that I wrote to the Japanese Embassy and the Japanese Ministry of Health, more or less to give them a detailed view of how GSK had previously claimed Paxil was safe for kids to take...when in actual fact they knew that it wasn't.

I never heard back from either one of them.

I also contacted GlaxoSmithKline in 2010, you can see the email I sent to them here.

In 2008, one year before I broke the news, Glaxo were recruiting kids for a clinical study. I say Glaxo, they, in actual fact were sponsoring the study.

The study was designed to compare the efficacy of oral paroxetine 10 to 40 mg/day (initial dose:10 mg/day) versus placebo administered once daily.

Oral paroxetine is a sickly orange syrup, I've been on it myself. It was the only safe way to taper from this highly addictive antidepressant.

And just who were being used as the guinea pigs in Japan?

One look at the inclusion study criteria would have showed you.

Ages Eligible for Study:7 Years to 17 Years.

Yup, that's right folks. Despite being dragged through numerous courts in the US where evidence was shown that Glaxo manipulated previous clinical trials in children, here they were again back in 2008 recruiting more kids.

A marketing campaign went out in the form of a poster... which I just happened to obtain from a source at Medwatcher Japan. Medwatcher were also furious at this particular clinical trial involving kids and Paxil.

Take a good look at the imagery used in the recruitment poster.



If a picture paints a thousand words, eh?


Well, folks... **drum roll** - the trial has been terminated.

**Cue a spectacular display of fireworks**

According to GSK's clinical trial database the study was terminated in 2011. They give no reasons as to why this study was terminated.

What we do know is that 56 kids were enrolled. 29 were in the Paxil group whilst the remaining 27 were in the placebo group.

The study results claimed that there were 3 reports of suicidal ideation in the placebo group but none in the Paxil group. [More about this later]

The subjects enrolled had to have a diagnosis of a depressive disorder before being allowed into the study.

So, it would appear that 3 of the kids taking placebo had suicidal ideation. Not one report in the Paxil group. Glaxo must have loved this.

Unfortunately for the Glaxo sponsored trial, Paxil didn't really show much efficacy.

Open the Outcome Measures on the Clinical Trials website and it tells us how Paxil failed.

Paxil didn't reduce the depression scores of the children sufficiently to be considered effective and the primary purpose of this study was efficacy. In this study all participants had to have a depression score of 45 or greater to be included. A 50% reduction on the CDRS-R is required to consider children have responded to treatment.

So, not only did Paxil not reach the standard for efficacy but in comparison to, let's say, fluoxetine, it would be seen to be less effective.

In the Fluoxetine studies [1] [2] the average decrease was 28.9%. In this Japanese study, the decrease was only 16.9% therefore the kids would not be considered to have responded to Paxil treatment.

No wonder the study was terminated, right?

It would appear that GlaxoSmithKline didn't want to expose the fact that Paxil is less effective than that of their competitor.

Another interesting finding from the Japanese study was the participants only had to have been free from any antidepressant for 1 week prior to the trial commencement.

Anyone who's anyone will know that one week off an antidepressant is hardly a time to get the champagne corks popping and decorate rooms with bunting and balloons. Any number of these participants could have been suffering withdrawal even before they were entered into the Japanese trial. Any of these patients suffering withdrawal, which remember can mimic depression, would have had immediate relief if they were selected for the Paxil arm of the trial. As the phases of the trial progressed they would have, obviously, reaped the benefits of Paxil but not for their apparent depression, their benefits from Paxil would have merely meant they would not be going through withdrawal anymore.

Take the three patients from the placebo arm of the study who, according to the results, suffered suicidal ideation, and we may just find that these three were also taking antidepressants a week or so before they entered the Japanese study.

Could their suicidal ideation have been caused by the withdrawal effects of the medication they were taking prior to the Japanese study?

Glaxo pretty much shot themselves in the foot with this study, a study that should never have taken place given the findings of the Paxil 329 study.

So, once the Japanese trial was over did the sponsors, GlaxoSmithKline, do any follow-up to see if these kids were okay? The doses used in the study were between 10mg and 40mg, the latter being enough to put a horse into a coma.

The withdrawal phase of the Japanese study lasted three weeks. Two weeks later the participants were contacted to see how they were.

Can you imagine a 7 year old child on 40mg of Paxil a day just having three weeks to taper? Even if the 7 year old was on a lower dose it's still mind-boggling how one adult human could give someone so young a pill known to increase suicidal thoughts, known to increase completion of suicide.

What on earth were GlaxoSmithKline thinking by using kids in a study for Paxil?

The Japanese public, particularly the children and adolescents, just don't know what a lucky escape they've had from this truly awful abomination of an antidepressant.

Bob Fiddaman

[1] Psychometric Properties of the Children's Depression Rating Scale–Revised in Adolescents - J Child Adolesc Psychopharmacol. 2010 December; 20(6): 513–516.
[2] Early Prediction of Acute Antidepressant Treatment Response and Remission in Pediatric Major Depressive Disorder - J Am Acad Child Adolesc Psychiatry. 2009 January; 48(1): 71.

Back stories:

Thursday, January 15, 2009 - Email to Japanese Embassy regarding New GSK paroxetine study in Children. ClinicalTrials.gov Identifier: NCT00812812

Friday, April 03, 2009 - Japan/GSK - 329 All Over Again!

Friday, April 03, 2009 - Email to Ministry of Health - Japan

Friday, May 21, 2010 - Email To GlaxoSmithKline Re; Paxil Study In Children

Friday, September 24, 2010 - HEY, GLAXO!... LEAVE THOSE KIDS ALONE

Friday, May 13, 2011 - Glaxo remain tight-lipped on new Japanese Paxil study in children.


Wednesday, May 18, 2011 - GSK Japan, Paxil Study in Kids Update







Monday, June 25, 2012

PAXIL: Unleashed in the East



GlaxoSmithKline have unleashed Paxil CR on Japanese citizens according to the Asahi Shimbun.

It's unknown whether GlaxoSmithKline pharmaceutical reps will be promoting its use 'off-label' to doctors. Glaxo did, however, carry out a Japanese Paxil study in 7 - 17 year olds a few years back, the results of which proved very little by way of safety and efficacy for this age group.

Despite previous failed clinical trials in children GlaxoSmithKline advertised for children to be part of a new clinical trial in Japan. The promotional poster [Fig 1] showed cartoon images of children feeling sad and tired whilst asking for recruits.

Fig 1


I previously covered Glaxo targeting Japanese children [Links at foot of post] and even telephoned their Japanese HQ to ask for the clinical trial results. Glaxo officials told me that, although the trials had finished, they did not have the results to hand.

With Paxil CR being unleashed I envisage lots of marketing spin from GSK Japan, the poster [above] is just another example of how they target children.

Here's the previous posts regarding Glaxo, Paxil and Japanese children.


Monday, January 12, 2009 - GSK Just won't stop trying to push paroxetine on children!.

Thursday, January 15, 2009 - Email to Japanese Embassy regarding New GSK paroxetine study in Children. ClinicalTrials.gov Identifier: NCT00812812.

Friday, April 03, 2009 - Email to Ministry of Health - Japan.

Friday, April 03, 2009 - Japan/GSK - 329 All Over Again!.

Saturday, July 25, 2009 - Paxil Study 329 All Over Again?.

Friday, May 21, 2010 - Email To GlaxoSmithKline Re; Paxil Study In Children.

Friday, September 24, 2010 - HEY, GLAXO!... LEAVE THOSE KIDS ALONE.

Friday, May 13, 2011 - Glaxo remain tight-lipped on new Japanese Paxil study in children..

Wednesday, May 18, 2011 - GSK JAPAN - PAXIL STUDY IN KIDS UPDATE.

Monday, May 23, 2011 - Are GlaxoSmithKline Japan Putting Children At Danger With Paxil Trial?.

Sunday, October 23, Japanese Paxil Study in Children Proves Very Little







Fid

ORDER THE PAPERBACK 'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman US and CANADA HERE OR UK HERE

AUSTRALIAN ORDERS HERE



Tuesday, January 31, 2012

Takeda Whistleblower



I'm loving all these whistleblower suits. Last year Cheryl Eckard blew the lid on GlaxoSmithKline's factory in Peurto Rico. A combination of poor quality pills, contamination and alleged black market selling of drugs from the plant saw Glaxo pay out a hefty fine. Eckard was earlier fired from her position after she brought it to the attention of her seniors that the Peurto Rican plant was in an appalling state.

Last week Allen Jones, another whistleblower, was vindicated for blowing the whistle on Johnson & Johnson. He learned that they were using underhand tactics to market their drug risperdal to children. A secret bank account was found by Jones that led him to the fraud. Like Eckard he too was fired from his position after he brought it to the attention of his peers.

Now we have a new whistleblower case set to hit the headlines.

Helen Ge was a former contractor at Takeda Pharmaceutical Co. Ltd. She learned that Takeda have been playing down risks of three of their drugs, particularly when combined with other drugs. Again, she was fired from her position when she brought this to the attention of her seniors, alleges the lawsuit filed by Baum Hedlund Aristei & Goldman PC and Ashcroft Sullivan LLC

The complaint alleges that Takeda knowingly steered doctors away from prescribing cheaper generics of Uloric, Prevacid and Dexilant, and also failed to report adverse events to the U.S. Food and Drug Administration.

“Takeda disregarded its duty to deal honestly with the government and with knowledge that its concealment and intentional misrepresentations would result in hundreds of millions, and perhaps billions of dollars in damage to government health care programs,” alleges the complaint.

What's startling about this particular whistleblower suit is that it appears that the elderly were at risk from Takeda's concealment, many elderly patients used Takeda's medication/s in combination with other drugs, drugs that Takeda allegedly knew could cause them serious problems and in some cases death.

This will be an interesting case to follow, particularly as Takeda are already under scrutiny for failing to warn patients taking their diabetes medication, Actos. A suit was filed in December last year that alleges Actos causes bladder cancer, the suit also makes claim to negligence, failure to warn, defective design and deceit by concealment.

More and more whistleblowers are coming forward it seems, which can only be good news for those of us that have been banging the drum loudly about the fraud that exists in Big Pharma.

Full complaint can be read HERE







  



Fid


ORDER THE PAPERBACK 'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman US and CANADA HERE OR UK HERE


AUSTRALIAN ORDERS HERE




Sunday, October 23, 2011

Japanese Paxil Study in Children Proves Very Little

How Glaxo recruited 7-17 year old children for their Japanese Paxil study


Back in 2009 I reported on how GlaxoSmithKline Japan were trialing out Paxil/Seroxat in children and adolescents. Over the following months I sought to find out why such a study was taking place, it seemed odd, to say the least, that GlaxoSmithKline were trying to prove their drug was safe in children and adolescents when it was blatantly obvious that it was not safe and effective.

The clinical trial, aimed at 7-17 year olds, went ahead, an 8 week trial which, it appears, was for the sole purpose of trying to prove one thing, at least that's the impression I get when reading the results.

What did Glaxo wish to push the boat out for? Well, my assumption, because I'm allowed to assume, is that Glaxo will use the results of this study to spin the suicidal ideation in kids claims that they hid in the earlier Paxil 329 study.

The 2009 study, which was completed earlier this year, shows a quite remarkable change.

You've guessed it folks.

Take a look at the following table:



You will note that the psychiatric disorders shows there were 3 reports on placebo whilst none were reported for Paxil. I't's hardly convincing seeing as there were only 29 subjects taking Paxil but I'm sure GlaxoSmithKline will use this to their advantage.

However, it would appear that the study proves nothing. Paxil was only slightly superior compared to placebo but it's all irrelevant anyhow.

Personally, I feel the only reason this study took place was to highlight the suicidal thoughts or lack of - Glaxo will no doubt spin this in future medical journals...or rather key opinion leaders handpicked by Glaxo will.

With just 29 subjects on Paxil they would have been lucky to pick up just one (3 per hundred is about 1 per 33). The low number of participants in the active treatment group pretty well ensured they most likely would not see emergent drug induced suicidality.

The study, like 329, has been manipulated, that's my opinion anyway, I'm still allowed an opinion aren't I?

If you look at the original exclusion criteria for this study you will see that it is not based on real-world prescribing. Remember just 1 subject in a hundred becoming suicidal because of the drug equates to 1000 subjects per million. And nobody knows for certain how many of those will go on to kill themselves - we do know that there have been many.

Each subject in this trial were asked a series of questions to determine if they were experiencing adverse reactions, the questions were, it appears, based on the CDRS-R rating scale

The CDRS-R is a brief rating scale based on a semi-structured interview with the child (or an adult informant who knows the child well). Designed for 6- to 12-year olds, and successfully used with adolescents, it can be administered in just 15 to 20 minutes and easily scored in a few minutes more. The interviewer rates 17 symptom areas (including those that serve as DSM-IV criteria for a diagnosis of depression): [SOURCE]

Impaired Schoolwork
Difficulty Having Fun
Social Withdrawal
Appetite Disturbance
Sleep Disturbance
Excessive Fatigue
Physical Complaints
Irritability
Excessive Guilt
Low Self-Esteem
Depressed Feelings
Morbid Ideation
Suicidal Ideation
Excessive Weeping
Depressed Facial Affect
Listless Speech
Hypoactivity

Most of these symptom areas are rated on a 7-point scale so the CDRS-R can capture slight but notable changes in a child's symptoms. This makes the scale ideal for monitoring symptoms during illness or remission. Other additions to the scale include suggested interview prompts and guidelines for integrating information from multiple informants.

Japanese Medwatch were concerned about this particular study, so concerned that they wrote the following to GSK Japan:


Click to read




The results of the trial have now been published online and can be viewed HERE

I anticipate they will appear [polished and spun] in medical journals soon.

Previous coverage of the Japanese Paxil Trials:


Monday, January 12, 2009 - GSK Just won't stop trying to push paroxetine on children!

Thursday, January 15, 2009 - Email to Japanese Embassy regarding New GSK paroxetine study in Children. ClinicalTrials.gov Identifier: NCT00812812

Friday, April 03, 2009 - Email to Ministry of Health - Japan

Friday, April 03, 2009 - Japan/GSK - 329 All Over Again!

Saturday, July 25, 2009 - Paxil Study 329 All Over Again?

Friday, May 21, 2010 - Email To GlaxoSmithKline Re; Paxil Study In Children

Friday, September 24, 2010 - HEY, GLAXO!... LEAVE THOSE KIDS ALONE

Friday, May 13, 2011 - Glaxo remain tight-lipped on new Japanese Paxil study in children.

Wednesday, May 18, 2011 - GSK JAPAN - PAXIL STUDY IN KIDS UPDATE

Monday, May 23, 2011 - Are GlaxoSmithKline Japan Putting Children At Danger With Paxil Trial?




Fid

ORDER THE PAPERBACK 'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman US and CANADA HERE
OR UK FROM CHIPMUNKA PUBLISHING

AUSTRALIAN ORDERS HERE




Monday, May 23, 2011

Are GlaxoSmithKline Japan Putting Children At Danger With Paxil Trial?



Some of you may know that I've been closely following the Paxil Clinical Trial in Japan. The trial, now completed, was labelled, "Clinical Evaluation of Efficacy and Safety of Paxil Tablets in Children and Adolescents with Major Depressive Disorder: Placebo-Controlled, Double-Blind, Parallel Group Study."

I wasn't the only one voicing my concerns about this particular trial. Medwatcher Japan, an independent Japanese drug watchdog, were also concerned. Back in July 2009 they wrote to GlaxoSmithkline Japan.

(1) The justification for determining the conduct of this study to be necessary and valid (how and why the conduct of the trial was determined to be necessary and valid)

(2) In particular, if the premise of conducting the clinical study is that effects can be expected for Japanese children, what information was used as justification for making that determination

(3) The most recent version of the study protocol (including records of previous revisions)

(4) Subject recruitment status (the names of the sites participating in the study to date, the number of people recruited at each site, and the Patient Information Sheet used at each site)

(5) Information on adverse events reported to date (information on number of emergent cases and clinical course of individual cases, etc.)

Concerned letter from Medwatch to GSK Japan



Now, for the first time, we can see GlaxoSmithKline's response. The original response was in Japanese. Here's the rough translation:


To: Mr. Toshihiro Suzuki
Representative of Medwatcher Japan

From: Public Relations Department of Glaxso Smith Kline
4-6-15 Sendagaya, Shibuya-ward Tokyo

Answer to "the demanding paper which requests for information disclosure about post-marketing clinical trial of anti-depressant PAXIL to children and adolescents"


The following shows the answer to "the demanding paper which requests for information disclosure about post-marketing clinical trial of anti-depressant PAXIL to children and adolescents" which we received 16 July this year. [2009]

Thank you for pointing that out. We answer each of your items regarding your demand with my company's point of view and related information. We will continue to pay more attention to this clinical trial taking into account your points.

Your continued support will be greatly appreciated.


Summary of the demanding of the paper.

"We demand you to open the following information about "Clinical evaluation for efficiency and safety of PAXIL for major depression disorder to child and adolesecen: placebo-controlled parallel-group double-blind trial"

(1) What is the reason of considering executing this clinical trial as necessary and suitable? (How did you go over the necessity and suitability of this clinical trial?)

(2) If the efficiency for Japanese children is expected as premises for executing the clinical trial, what is the information that backed up your decision?


[Answer]
Major depressant disorder (MDD) is one of the conduct disorders that can begin in children and adolescents. It can cause academic failure, absence without notice, alcohol intake and use of drugs. It can also cause suicide. The prevalence rate of MDD is presumed to be about 2% in children and about 4-8% in adolescents in Europe and the United States.

But it is fact that examination of SSRI's, including PAXIL for MDD to children and adolescents, has not been sufficiently executed even in foreign countries. On the other hand, as you point out in the demanding paper, there is a situation that most psychotropic drugs are used as non-approved indications in Japanese psychiatric treatment for children and adolescents. Therefore, in order to utilize such drugs properly, it is needed to establish evidence for efficacy and safety of them by executing a clinical trial in Japan.

We consider that the result of our clinical trial as help for medical doctor's decisions in the treatment for children and adolescents. Therefore, we planned to execute the post-marketing clinical trial in order to confirm the dosage and administration for children and the efficacy and safety for the children's group.

On 24 August 2006, re-examination period for PAXIL going with post-marketing clinical trial was deliberated at the First Committee for Drugs in Pharmaceutical and Food Hygiene Council. In the committee, a committee member said that "Though the efficacy of PAXIL was not verified in other countries clinical trials, there are opinions from clinical sites in Japan that SSRI's were effective for child's depression."

A psychiatric society is demanding the use of PAXIL.

The Japanese Society for Child and Adolescent Psychiatry filed a petition entitled: "Demand for the Ministry of Health, Labour and Welfare about psychotropic drugs for children and adolescents (Date: 30 May 2007)". So we recognize that clinical site demands strongly.

In addition, we prescribed various care for safety of trialists in the protocol. Also we take a measure for safety of trialists bv explaining sufficiently about warning signs and symptoms of MDD, especially suicide related event to trialists' parents.


(3) Latest edition of test protocol (including the log of revised version in the past)

[Answer]
This test protocol has already opened in the Clinical Study Register
(http://www.gsk-clinicalstudyregister.com/protocol_detail.jsp?protocolId=112487&studyId=24207&compound=Paroxetine+10mg+Tablet)


(4) Real situation of recruit for trialist (Name of each participating facility, number of people recruited in each facility and briefing paper for trialist used in each facility in present time)

[Answer]
Outline of participating facilities and information about recruits in each facility is gradually opened in ClinicalTrials.gov (Please refer http://clinicaltrials.gov/ct2/home and "Location and Contact Information" in the test protocol)


(5) Information about adverse events so far (number of event and any information about clinical course of each case)

[Answer]
Now, the clinical trial is in action we don't have any information about adverse events defined. By 30 September 2009, there were no serious adverse events reported about this clinical trial.


Answer from GSK Japan [Japanese]



So, judging by this response from GlaxoSmithKline Japan, it would appear that this study has been carried out because the Japanese Society for Child and Adolescent Psychiatry are demanding the use of Paxil in children and adolescents!

Furthermore, it seems apparent that GSK Japan have warned children and adolescents on this trial about the dangers of MDD causing suicide - but did they warn the subjects and their parents that Paxil can also induce suicide and/or suicidal thoughts?

What is wrong with GlaxoSmithKline saying, "No, we have already carried out trials for the safety and efficacy of Paxil in children and adolescents, there is no need for another trial?"

Well, why would they?

This response from GlaxoSmithKline should come as no surprise. I have never known a company who show such obvious disdain when it comes to the safety of children. Quite how they thought they could get away with this trial still baffles me? Did they think people, such as myself, wouldn't eventually find out? My only surprise is that GSK Japan didn't throw in the line, "Paxil has benefited millions of people worldwide."

It would now appear that drugs that are not recommended for use in children can be re-trialled in Japan on the demands of a psychiatric association. The question that has to be asked is why?

The members of the Japanese Society for Child and Adolescent Psychiatry Council can be viewed HERE

It is not known if any of its members have financial ties or other conflicts of interests that connect to GlaxoSmithKline Japan, I'd bet my left nut that there are ties - there always is!


Although the trial was concluded in February 2011, GlaxoSmithKline Japan have refused to send me the conclusion of the trial, citing; "The expected official release was planned to be October."

One can only begin to imagine the heartache many families in Japan are going through right now. The recent earthquake and tsunami killed many. That will have a knock on effect of all those family and friends who have lost loved ones. Children will have lost mothers, fathers, brothers sisters, grandparents, friends and even loved pets. What better way to treat their loss than a pill that has been promoted in Japan with advertising campaigns such as an advertisement where a beautiful young lady comes out all smiles and says, "I went to a doctor and now I'm happy.' You know, depression is not that easy. And if it is that easy, it might not be depression."

In contrast, and what Glaxo Japan have failed to acknowledge with regard to this trial is the Bloomberg report from 2007, which ran with the headline: 'Japan Says Suicidal Cases Rise Among Paxil Users.'

The number of patients who committed suicide or planned suicide after taking GlaxoSmithKline Plc's antidepressant Paxil rose to 39 last year, Japan's Ministry of Health, Labor and Welfare said. [SOURCE]

With all the evidence pointing to Paxil NOT being safe and effective in children and adolescents, GlaxoSmithKline Japan, it appears, are sticking a huge index finger up to the rest of the world. This clinical trial should never have been given the go-ahead. GlaxoSmithKline should be hauled over the coals about this. I suspect drug regulators around the world will turn a blind eye, hey, it's not our problem after all is it?

Finally, this is how GSK promoted this children's trial, it's a poster asking for recruits. Are you, like me, sickened by this poster?



Special thanks to Medwatcher Japan


Bob Fiddaman

Here are the links where I previously wrote about this study:

Thursday, January 15, 2009 - Email to Japanese Embassy regarding New GSK paroxetine study in Children. ClinicalTrials.gov Identifier: NCT00812812

Friday, April 03, 2009 - Japan/GSK - 329 All Over Again!

Friday, April 03, 2009 - Email to Ministry of Health - Japan

Saturday, July 25, 2009 - Paxil Study 329 All Over Again?

Friday, May 21, 2010 - Email To GlaxoSmithKline Re; Paxil Study In Children

Friday, September 24, 2010 - HEY, GLAXO!... LEAVE THOSE KIDS ALONE

Friday, May 13, 2011 - Glaxo remain tight-lipped on new Japanese Paxil study in children.

Wednesday, May 18, 2011 - GSK JAPAN - PAXIL STUDY IN KIDS UPDATE







Wednesday, May 18, 2011

GSK JAPAN - PAXIL STUDY IN KIDS UPDATE



Well, I'd love to tell you that the Paxil study in children that was carried out in Japan was deemed a failure. Truth is, I don't know and Glaxo, it appears, remain to be tight lipped over this particular study.

A few days ago I wrote how they [GSK] had promised to get back to me regarding my query of the outcome of the NCT00812812 clinical trial, "Paxil Japanese Post Marketing Paediatric Study in Depression (Double-blind, Placebo Controlled Study)"

Remarkably the Clinical Trials webpage has now been updated regarding this trial...no conclusion though.

The study was completed back in February this year [2011].

Glaxo wrote me this morning with the following:

Thank you for contacting the GSK Clinical Support Helpdesk.

Unfortunately conclusion can’t be disclosed before the official CTR is released.

Adding in a further email:

The expected official release was planned to be October.

Thanks for clearing that up.

I wrote back asking if Paxil was currently recommended for use in children between the ages of 7-17 in Japan?

No reply.



For back stories regarding this trial visit:


Thursday, January 15, 2009 - Email to Japanese Embassy regarding New GSK paroxetine study in Children. ClinicalTrials.gov Identifier: NCT00812812

Friday, April 03, 2009 - Japan/GSK - 329 All Over Again!

Friday, April 03, 2009 - Email to Ministry of Health - Japan

Saturday, July 25, 2009 - Paxil Study 329 All Over Again?

Friday, May 21, 2010 - Email To GlaxoSmithKline Re; Paxil Study In Children

Friday, September 24, 2010 - HEY, GLAXO!... LEAVE THOSE KIDS ALONE

Friday, May 13, 2011 - Glaxo remain tight-lipped on new Japanese Paxil study in children.


Fid

Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal

ORDER THE PAPERBACK - 'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT [PAXIL] SCANDAL'

US/CANADA COPIES HERE OR UK/IRELAND FROM CHIPMUNKA PUBLISHING

Friday, May 13, 2011

Glaxo remain tight-lipped on new Japanese Paxil study in children.




Some of you may remember I highlighted sometime ago on this blog that GlaxoSmithKline Japan were carrying out studies with Paxil/Seroxat in children. [See links at foot of this article]

Naturally I was, like many others, appalled at Glaxo's need to carry out such a study, particularly as they had already deemed Paxil unfit [unsafe and ineffective] for this particular age group. [7-17 years]

It seems I wasn't alone in voicing my concerns.

The following is a letter sent to GlaxoSmithKline from Yakugai Ombudsperson Medwatcher Japan and Toshihiro Suzuki, Representative. It's dated July 16 2009.

Demand for Publication of Information Related to Post-Marketing Clinical Trials on Children and Adolescents Using the Antidepressant Paxil.

I. Purpose of the Demand

We are requesting the following information on "Clinical Evaluation of Efficacy and Safety of Paxil Tablets in Children and Adolescents with Major Depressive Disorder: Placebo-Controlled, Double-Blind, Parallel Group Study."

(1) The justification for determining the conduct of this study to be necessary and valid (how and why the conduct of the trial was determined to be necessary and valid)

(2) In particular, if the premise of conducting the clinical study is that effects can be expected for Japanese children, what information was used as justification for making that determination

(3) The most recent version of the study protocol (including records of previous revisions)

(4) Subject recruitment status (the names of the sites participating in the study to date, the number of people recruited at each site, and the Patient Information Sheet used at each site)

(5) Information on adverse events reported to date (information on number of emergent cases and clinical course of individual cases, etc.)

Both the Yakugai Ombudsperson and Suzuki added:

"We strongly desire the disclosure of detailed information and a public re-examination of the question of whether it is truly necessary and valid to conduct a new clinical trial with Japanese children on a drug whose efficacy could not be confirmed in overseas clinical trials and which furthermore is suggested to potentially increase the risk of suicide."

I echo their sentiments. Are GlaxoSmithKline suggesting that it may be okay for Japanese children to take Paxil? I cannot quite grasp why Glaxo would carry out such a study on this age group.

The letter can be viewed in PDF format here:





According to the GlaxoSmithKline web page, the study is now completed. However, the results of that study still remain a mystery.


I emailed GlaxoSmithKline this morning to ask them for the conclusion of study NCT00812812, I anticipated either silence from them or a reply stating that under some twisted pharmaceutical law they are not allowed to divulge such information.

I was wrong. Their response was even more elusive:


Dear Mr. Fiddaman,

Please be advised that we have sent your request to our Business Representatives in regards to your question. Someone will contact you in the next few days.



No time like the present - I phoned them and asked if they could give me the results of the trial, they informed me that my request had been passed on to a "business representative" - they also asked me if I was a doctor or patient, I told them I was a former patient and writer and added that I write specifically about paroxetine [Paxil]

When asked if the trial results would be made public within the next 48 hours, I was told, "We don't know, we have to wait until the business representative gets back to us."

Jeez, it would be easier to ask Shania Twain if she wanted to play a game of hide the salami with me - at least I'd get a definitive answer!

Rather than wait for their "Paxil has benefited millions of people world-wide" type of response I thought I'd press ahead with this post, if only to highlight that Glaxo are [once again] not being transparent with regard to clinical trials with Paxil and children!




Here are the links where I previously wrote about this study:

Thursday, January 15, 2009 - Email to Japanese Embassy regarding New GSK paroxetine study in Children. ClinicalTrials.gov Identifier: NCT00812812

Friday, April 03, 2009 - Japan/GSK - 329 All Over Again!

Friday, April 03, 2009 - Email to Ministry of Health - Japan

Saturday, July 25, 2009 - Paxil Study 329 All Over Again?

Friday, May 21, 2010 - Email To GlaxoSmithKline Re; Paxil Study In Children

Friday, September 24, 2010 - HEY, GLAXO!... LEAVE THOSE KIDS ALONE

Fid


Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal

ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT [PAXIL] SCANDAL' By Bob Fiddaman
US/CANADA COPIES HERE OR UK/IRELAND FROM CHIPMUNKA PUBLISHING

Please contact me if you would like a guest post considered for publication on my blog.